![Treatment of rheumatoid arthritis with rituximab: An update and possible indications - ScienceDirect Treatment of rheumatoid arthritis with rituximab: An update and possible indications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1568997206000243-gr1.jpg)
Treatment of rheumatoid arthritis with rituximab: An update and possible indications - ScienceDirect
![Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-01789-0/MediaObjects/41591_2022_1789_Fig1_HTML.png)
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial | Nature Medicine
![Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fncprheum0424/MediaObjects/41584_2007_Article_BFncprheum0424_Fig1_HTML.jpg)
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
![Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/64149bae-86ee-4d1d-92a7-98c8f7996536/gr1.gif)
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial - The Lancet Rheumatology
![PDF) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration PDF) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration](https://i1.rgstatic.net/publication/295503309_Effectiveness_of_two_different_doses_of_rituximab_for_the_treatment_of_rheumatoid_arthritis_in_an_international_cohort_Data_from_the_CERERRA_collaboration/links/577260c608aeef01a0b629ab/largepreview.png)
PDF) Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: Data from the CERERRA collaboration
![Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating](https://ard.bmj.com/content/annrheumdis/69/9/1629/F1.large.jpg)
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating
![Algorithm for the use of rituximab in patients with RA. Broken line... | Download Scientific Diagram Algorithm for the use of rituximab in patients with RA. Broken line... | Download Scientific Diagram](https://www.researchgate.net/publication/5388771/figure/fig1/AS:601699085479944@1520467649256/Algorithm-for-the-use-of-rituximab-in-patients-with-RA-Broken-line-represents-an.png)
Algorithm for the use of rituximab in patients with RA. Broken line... | Download Scientific Diagram
![Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-022-02826-6/MediaObjects/13075_2022_2826_Fig1_HTML.png)
Rheumatoid arthritis patients initiating rituximab with low number of previous bDMARDs failures may effectively reduce rituximab dose and experience fewer serious adverse events than patients on full dose: a 5-year cohort study
![Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay](https://consumer.healthday.com/media-library/eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJpbWFnZSI6Imh0dHBzOi8vYXNzZXRzLnJibC5tcy8yNzg5NjkyNS9vcmlnaW4uanBnIiwiZXhwaXJlc19hdCI6MTcwMjkwNTE5NH0.DEzsb9DvZsqnlMPIb-oTqh13ZkYxwPuofRpc2YMm-Qg/image.jpg?width=1245&height=700&quality=85&coordinates=0%2C91%2C0%2C92)
Ultra-Low Dose of Rituximab Safely Eases Rheumatoid Arthritis Over Long Term: Study - Consumer Health News | HealthDay
![VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine VisualAbstract: Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2021/02/2MM_2.7.2021_3_RA-scaled.jpg)